IDEAYA Biosciences, Inc. (IDYA)
Largest Insider Buys in Sector
IDYA Stock Price History Chart
IDYA Stock Performance
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers …
Insider Activity of IDEAYA Biosciences, Inc.
Over the last 12 months, insiders at IDEAYA Biosciences, Inc. have bought $0 and sold $19.26M worth of IDEAYA Biosciences, Inc. stock.
On average, over the past 5 years, insiders at IDEAYA Biosciences, Inc. have bought $3.45M and sold $11.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,062 shares for transaction amount of $67,408 was made by BVF PARTNERS L P/IL (10 percent owner) on 2020‑06‑30.
List of Insider Buy and Sell Transactions, IDEAYA Biosciences, Inc.
| 2024-05-29 | Sale | Chief Scientific Officer | 28,500 0.038% | $36.24 | $1.03M | +3.01% | ||
| 2024-05-16 | Sale | President and CEO | 34,433 0.0453% | $41.81 | $1.44M | -10.02% | ||
| 2024-05-15 | Sale | President and CEO | 83,856 0.112% | $42.90 | $3.6M | -11.97% | ||
| 2024-05-14 | Sale | President and CEO | 56,711 0.0746% | $41.61 | $2.36M | -10.50% | ||
| 2024-02-09 | Sale | President and CEO | 23,557 0.0351% | $45.54 | $1.07M | -13.46% | ||
| 2024-02-09 | Sale | See Remarks | 2,000 0.003% | $46.02 | $92,045 | -13.46% | ||
| 2024-02-08 | Sale | President and CEO | 75,815 0.1121% | $45.15 | $3.42M | -11.32% | ||
| 2024-02-01 | Sale | President and CEO | 628 0.0009% | $45.00 | $28,260 | -10.41% | ||
| 2024-01-22 | Sale | See Remarks | 2,000 0.0028% | $42.03 | $84,050 | -5.41% | ||
| 2024-01-16 | Sale | President and CEO | 62,739 0.0965% | $40.17 | $2.52M | +0.52% | ||
| 2024-01-12 | Sale | President and CEO | 12,261 0.0191% | $40.04 | $490,913 | +1.98% | ||
| 2024-01-12 | Sale | See Remarks | 2,000 0.003% | $38.01 | $76,026 | +1.98% | ||
| 2023-12-15 | Sale | President and CEO | 75,000 0.1165% | $35.03 | $2.63M | +13.36% | ||
| 2023-12-15 | Sale | Chief Legal Officer | 10,000 0.0155% | $35.04 | $350,371 | +13.36% | ||
| 2023-12-14 | Sale | See Remarks | 2,000 0.0031% | $34.00 | $68,002 | +16.99% | ||
| 2023-11-03 | Sale | Chief Legal Officer | 5,163 0.0085% | $30.09 | $155,360 | +34.29% | ||
| 2023-09-12 | Sale | Chief Legal Officer | 1,000 0.0018% | $30.00 | $30,005 | +30.51% | ||
| 2023-09-05 | Sale | Chief Legal Officer | 1,737 0.0031% | $30.03 | $52,160 | +33.04% | ||
| 2023-09-01 | Sale | See Remarks | 2,000 0.0035% | $30.01 | $60,016 | +28.75% | ||
| 2023-09-01 | Sale | Chief Legal Officer | 2,100 0.0037% | $30.03 | $63,063 | +28.75% |
Insider Historical Profitability
| DIEKMAN JOHN D | director | 2844545 3.3671% | $30.50 | 1 | 0 | <0.0001% |
| SHANNON TIMOTHY M | director | 2660713 3.1495% | $30.50 | 1 | 0 | <0.0001% |
| CANAAN X L.P. | 10 percent owner | 2660713 3.1495% | $30.50 | 1 | 0 | <0.0001% |
| Alexandria Venture Investments, LLC | 10 percent owner | 432384 0.5118% | $30.50 | 1 | 0 | <0.0001% |
| BVF PARTNERS L P/IL | 233150 0.276% | $30.50 | 3 | 1 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $445.61M | 12.22 | 10.16M | +1,043.34% | +$406.64M | 0.03 | |
| BlackRock | $261.76M | 7.18 | 5.97M | +9.73% | +$23.2M | 0.01 | |
| Federated Hermes | $213.08M | 5.84 | 4.86M | +25.04% | +$42.66M | 0.49 | |
| The Vanguard Group | $182.35M | 5 | 4.16M | +19.56% | +$29.84M | <0.01 | |
| T. Rowe Price | $177.82M | 4.88 | 4.05M | +13.63% | +$21.34M | 0.02 |